[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版). 肝脏,2015,20:915-932.
[2] Ma YJ, He M, Han JA, et al. A clinical study of HBsAg- activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand J Immunol, 2013,78: 387-393.
[3] 冯艳红,吴卫锋,常家宝,等. DC-CIK联合回输治疗HBeAg阳性慢性乙型肝炎Treg细胞的变化. 江苏医药,2016,42: 584-585.
[4] Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol, 2005,3: 819-828.
[5] 袁海宁,邓一鸣. γ-干扰素与丹参治疗慢性乙型病毒性肝炎肝纤维化的近期疗效比较.广西医科大学学报, 2007,24: 797-798.
[6] 翁红雷,蔡卫民,王宝恩,等. 重组干扰素γ治疗慢性乙型肝炎肝纤维化临床研究.中华医学杂志,2003,83:943-947.
[7] Lin FC, Young HA. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev, 2014,25: 369-376.
[8] 史青竹, 赵智, 石新慧,等.Ⅰ型干扰素的抗病毒机制研究进展. 军事医学, 2015,39: 557-560.
[9] Wu YJ, Cai WM, Li Q, et al. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int, 2011,10: 151-157.
[10] 瞬时弹性成像技术(TE)临床应用共识专家委员会.瞬时弹性成像技术(TE)临床应用专家共识(2015年). 中国肝脏病杂志(电子版), 2015,7: 12-18. |
